Lifecore to Be Acquired by Webster Equity Partners for $6.28/Share Cash Plus CVRs Worth Up to $160M
LFCR sits 19% above its 52-week low of $3.625.
Summary
Lifecore Biomedical agreed to be acquired by Webster Equity Partners for $6.28 per share in cash plus CVRs worth up to $160 million in aggregate — a 49.5% premium to the last closing price. The deal resolves the company's preferred stock redemption crisis and includes a 30-day go-shop period.
Updates
· SEC SCHEDULE 13D/A — Legion Partners reports 17.3% beneficial ownership and entered a voting agreement to support the Webster merger.
· SEC DEFA14A — The merger agreement includes a 30-day go-shop period and CVR milestones: $30M for 2028 revenue, $45M for 2029 revenue, and $85M for 2030 EBITDA, with partial payments possible.
Key Events · M&A and Partnerships · LFCR
-
Acquisition by Webster Equity Partners
Lifecore entered into a definitive merger agreement on September 27, 2026, to be acquired by Webster Equity Partners. Common stockholders receive $6.28 per share in cash at closing, a 49.5% premium to the September 25, 2026 closing price.
-
CVRs Add Up to $160M in Contingent Value
Each common share also receives one non-tradable CVR. Milestone payments are $30M (2028 revenue), $45M (2029 revenue), and $85M (2030 EBITDA). At full payout, total consideration reaches $9.67 per share, a 130.2% premium.
-
Resolves Preferred Stock Redemption Crisis
The deal addresses the $52.1 million Series A Preferred redemption demanded by activist investors 22NW Fund and Legion Partners by December 28, 2026. Preferred holders receive the Conversion Amount (~$50.2M as of June 30, 2026) plus CVRs.
-
Fully Committed Financing
Webster secured $400 million in equity commitments plus $180 million in debt financing ($115M term loans, $30M revolver, $35M Alcon term loan). The merger is not subject to any financing condition.
Analysis · LFCR · Life Sciences
Lifecore Biomedical has agreed to be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Common stockholders receive $6.28 per share in cash at closing — a 49.5% premium to the September 25, 2026 closing price — plus one non-tradable contingent value right (CVR) per share. The CVRs can pay up to $160 million in aggregate if Lifecore hits revenue milestones in 2028 ($30M), 2029 ($45M), and an EBITDA milestone in 2030 ($85M). At full CVR payout, total consideration reaches $9.67 per share, a 130.2% premium. The deal resolves the company's liquidity crisis: activist investors 22NW Fund and Legion Partners had demanded $52.1 million in preferred stock redemption by year-end that Lifecore could not fund without lender consent. Webster has secured $400 million in equity commitments plus $180 million in debt financing ($115M term loans, $30M revolver, $35M Alcon term loan), with no financing condition. The merger includes a 30-day go-shop period allowing Lifecore to solicit superior offers, and voting agreements lock in support from Wynnefield and Legion stockholders — the same activists who forced the company's hand. The deal is expected to close at the end of Q4 2026, subject to stockholder approval and HSR clearance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFCR was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.